The below-mentioned healthcare stocks have provided significant returns in the last six months and have come up with major updates today (i.e. 15th July 2019). Let’s take a look at these updates.
Rhinomed Limited (ASX: RNO)
A Melbourne-based technology firm, Rhinomed Limited (ASX: RNO) has achieved a significant milestone by successfully registering it’s Pronto™ rechargeable, dual action, vapour release technology with the European Authority. In an announcement made on 15th July 2019, the company confirmed that its Pronto™ rechargeable technology has been registered as a Class I medical device with European Authority, which has given this technology a CE Mark, a significant step in ensuring that the Pronto range can be sold globally. It is expected that this achievement will further help the company in its business development activities.
Following the release of this news, the share price of the company increased by 6.122% during the intraday trade.
Pronto Sleep and Pronto Clear (Source: Company Reports)
If used with the Mute’s stenting action, this technology can improve nasal airflow and deliver a soothing blend of pure essential oils, which could help in getting better sleep.
In the release, the company has also announced that its Pronto range is now available online via www.prontosleep.com and www.prontoclear.com. Besides that, around 1,000 Walgreens stores across the USA are currently in the process of being listed with Amazon.com in the USA.
The company is planning to showcase its entire technology range at the upcoming 2019 NACDS Total Store Expo, which will be held in August in Boston, USA. With these new achievements, the company is rapidly progressing to gain from multibillion-dollar US sleep and nasal congestion markets.
In the past six months, the company’s shares have provided a return of 22.50% as on 12th July 2019. At market close on 15th July 2019, the company’s stock traded at $0.260, with a market capitalisation of circa $34.77 million and a daily volume of ~ 127,436. The stock’s 52-week high and low price stands at $0.410 and $0.140, with an average volume of ~181,917.
Telix Pharmaceuticals Limited (ASX: TLX)
A clinical-stage biopharmaceutical company, Telix Pharmaceuticals Limited (ASX: TLX) has finalised the formal meeting outcomes with the US Food and Drug Administration (FDA) in relation to the pre-Phase III Investigational New Drug (IND) meeting held with the FDA on the 17th of June. The meeting was requested to review the proposed inclusion of American patients into Telix’s ZIRCON (Zirconium Imaging in Renal Cancer Oncology) study.
With regards to the manufacturing package, the FDA has clarified the scope of manufacturing data to be included in the Phase III submission, including supporting stability studies and data to support product safety and efficacy. The company has also confirmed that it possesses all the requested supporting data.
In the meeting, the FDA provided positive feedback on the ZIRCON study design and made no objection to the company’s plan to enrol ~80 US patients into the trial. Further, the FDA made additional recommendations on the statistical analysis plan for powering the study in addition to the capture and analyses of non-ccRCC pathologic subtypes. Telix Pharmaceuticals is going to incorporate this feedback into the final submitted protocol design.
In the next 60 days, the company expects to file the complete Phase III IND package. FDA review of Telix’ IND submission will occur concurrently with ongoing ZIRCON study patient recruitment in Europe and Australia.
The company’s shares were placed in a trading halt on 15th July 2019, pending a release of an announcement regarding a proposed capital raise. The stock last traded at $1.670, with a market capitalisation of $364.67 million as on 12th July 2019. In the past six months, the company’s shares have provided a return of 121.19% as on 12th July 2019.
Botanix Pharmaceuticals Ltd (ASX: BOT)
A Perth-based, clinical stage cannabinoid company, Botanix Pharmaceuticals Ltd (ASX: BOT) has unveiled encouraging data from recently conducted studies around its cannabidiol antimicrobial platform and a new development program ‘AB 2367’. The studies have demonstrated that the new development program has potent activity against human and veterinary hypervirulent strains of Clostridium difficile, a gram-positive, spore-forming and toxin-producing bacterium, which infects the intestinal tract. Clostridium difficile (C. difficile) is a serious worldwide public health threat and is the most commonly acquired hospital infection globally.
The results from these new studies have shown that AB 2367 is a potent antibiotic effective against human and veterinary hypervirulent strains of the Gram-Positive bacteria C. difficile. And in addition, the studies have shown that, AB 2367 is effective against the super hypervirulent epidemic strain of C. difficile, ribotype 027 and 078.
This new data provides strong support for the growing cannabidiol antimicrobial platform under development by Botanix. The management of Botanix Pharmaceuticals is overwhelmed by the potential of this new data.
Following the release of this news, the company’s shares went up by 14.286% as on 15th July 2019.
Recently, the company announced the groundbreaking discovery that MRSA (Methicillin Resistant Staphylococcus Aureus) superbugs do not develop resistance to cannabidiol and now has shown an effective antibiotic against C. difficile. Both of these announcements are significant discovery from the company’s end.
Currently, the company is assessing options for the development of a broader antimicrobial platform as it awaits finalisation of ongoing acne and atopic dermatitis Phase II studies.
In the past six months, the company’s shares have provided a return of 187.67% as on 12th July 2019. At market close on 15th July 2019, the company’s stock was trading at $0.240, with a market capitalisation of circa $162.55 million and a daily volume of ~ 11,781,601. The stock’s 52-week high and low price stands at $0.290 and $0.067, with an average volume of ~4,163,565.
PharmAust Limited (ASX: PAA)
A clinical-stage oncology company, PharmAust Limited (ASX: PAA) has received ethics approval from the NSW Department of Primary Industry’s Secretary’s Animal Care & Ethics Committee to recommence Phase II clinical trials in pet owners’ dogs with cancer using its newly formulated tablet.
Following the release of this news, the share price of the company increased by 6% during today’s intraday trade.
Earlier, the company received approval for its anti-cancer program in dogs using the currently approved liquid formulation of monepantel, however, despite demonstrating strong signs of anti-cancer efficacy, this formulation was unpalatable and could not be used effectively. Subsequently, the company developed a new taste-neutral tablet now approved for Phase II, which the authority believes is a new veterinary research product.
The company expects tablets delivery from the USA in August/September and shortly after, it will commence the recruitment for Phase II trials. The company is planning to first treat dogs with B-cell lymphoma, which is the most prevalent canine cancer.
In the past six months, the company’s shares have provided a return of 31.21% as on 12th July 2019. At market close on 15th July 2019, the company’s stock was trading at $0.053, with a market capitalisation of circa $14.01 million and a daily volume of ~850,596. The stock’s 52-week high and low price stands at $0.058 and $0.030, with an average volume of ~450,578.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.